FLT-PET for the assessment of systemic sarcoidosis including cardiac and CNS involvement: a prospective study with comparison to FDG-PET

EJNMMI Research

Table 4 Summary of cardiac PET findings in subjects with CS (N = 12*)

	FLT-PET	FDG-PET	p value
# of subjects with cardiac uptake (%)	6 (50%)	7 (58%)	0.70
# of LV segments involved ± SD	6.2 ± 1.5	7.3 ± 3.5	0.50
# of segments in LAD^† territory ± SD	2.5 ± 1.0	2.7 ± 1.3	0.75
# of segments in LCX territory ± SD	1.3 ± 1.0	1.7 ± 1.4	0.59
# of segments in RCA territory ± SD	2.5 ± 0.8	2.9 ± 1.5	0.61
# of subjects with RV uptake (%)	2 (17%)	4 (33%)	0.17
Maximum LV SUV ± SD	15.4 ± 4.4	13.7 ± 6.0	0.58
LV SUV_Total ± SD	27.7 ± 8.4	45.7 ± 33.1	0.22
Maximum RV SUV ± SD ^α	2.4 ± 0.4	4.6 ± 5.0	0.59
	Perfusion PET
# of subjects with perfusion defects (%)	10 (83%)
SRS ± SD	6.2 ± 4.6
SRS in LAD territory ± SD	3.2 ± 2.9
SRS in LCX territory ± SD	1.0 ± 1.3
SRS in RCA territory ± SD	2.0 ± 1.9

LV left ventricle, RV right ventricle, LAD left anterior descending artery, LCX left circumflex artery, RCA right coronary artery, SUV standardized uptake value
*Only subjects satisfying the HRS criteria (N = 12/14) were included in this analysis
^†Vascular territories defined as per AHA 17 segment model [13]
^αIncludes only those subjects with evidence of RV uptake